Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Sponsor: Bangladesh Medical University
Summary
The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma. The study aims to determine whether the addition of TACE to lenvatinib results in improved tumor response compared with lenvatinib alone in a real-world clinical setting.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2025-04-08
Completion Date
2026-09-30
Last Updated
2026-02-13
Healthy Volunteers
No
Interventions
TACE (transarterial chemoembolization) combined with targeted therapy (Lenvatinib)
Transarterial Chemoembolization will be done in the radiology department by an interventional radiologist. Lenvatinib will be started after 7 days following TACE according to body weight (8mg/day in patients with a body weight \<60 kg and 12mg/day in patients with a body weight of 60 kg or more)
Lenvatinib
Lenvatinib will be started according to body weight ((8mg/day in patients with a body weight \<60 kg and 12mg/day in patients with a body weight of 60 kg or more)
Locations (1)
Department of Hepatology, Bangladesh Medical University
Dhaka, Bangladesh